Skip to main content
Premium Trial:

Request an Annual Quote

BioForce Nanosciences Closes $300K Convertible Debt Financing

NEW YORK (GenomeWeb News) – BioForce Nanosciences said today that it has closed a $300,000 convertible debt financing from its largest shareholder.
 
The Ames, Iowa-based company said the investment involved issuing $300,000 of convertible secured promissory notes, which are convertible into shares of the firm’s common stock at $.30 per share, and the issuance of 900,000 warrants for the company’s common stock at $.30 per share.
 
Investors in this round include FCPR SGAM AI Biotechnology Fund and three of BioForce’s executive officers: President and CEO Kerry Frey, Chief Science Officer Eric Henderson, and CFO Greg Brown.
 
BioForce’s Nano eNabler system is used in developing biosensors and therapeutic agents based on single cell analysis.
 
Brown said that the deal is “an important piece of our overall financing strategy for 2008, which will allow us to support our expanded distribution network and development of the market for our recently announced custom patterned surfaces offering.”

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.